

## NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

by postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

**Submitted to Vicore Pharma Holding AB (publ) no later than Monday 10 May 2021.**

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 at the annual general meeting on 11 May 2021. The voting right is exercised in accordance with the below marked voting options.

Shareholder	Personal identity number/registration number

**Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity):** I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

**Assurance (if the undersigned represents the shareholder by proxy):** I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

<b>Place and date</b>	
<b>Signature</b>	
<b>Clarification of signature</b>	
<b>Telephone number</b>	<b>E-mail</b>

### Instructions:

- Complete the information above
- Select the preferred voting options below
- Print, sign and send the form in the original to Vicore Pharma Holding AB (publ), att: Nina Carlén, Kronhusgatan 11, SE-411 05 Göteborg, Sweden. A completed and signed form may also be submitted electronically and shall, in such case, be sent to [nina.carlen@vicorepharma.com](mailto:nina.carlen@vicorepharma.com)
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is

the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign

- A power of attorney shall be enclosed if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form
- **Please note that a shareholder whose shares are registered in the name of a bank or securities institute must register its shares in its own name to vote.** Instructions regarding this are included in the notice convening the meeting

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be received by the company no later than 10 May 2021. An advance vote can be withdrawn up to and including 10 May 2021 by contacting [nina.carlen@vicorepharma.com](mailto:nina.carlen@vicorepharma.com).

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and complete proposals on the company's website. The complete proposals are provided on the company's website no later than three weeks before the general meeting.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website [www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf](http://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf).

## Annual general meeting in Vicore Pharma Holding AB (publ) on Tuesday 11 May 2021

The options below comprise the proposals submitted by the board of directors and the nomination committee which are included in the notice convening the annual general meeting.

<b>1. Election of chairman of the annual general meeting</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>2. Election of one or two persons to verify the minutes</b>
<b>2.1 Kjell Stenberg or, in the event of impediment, the person instead appointed by the board of directors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>2.2 Johannes Eckerstein or, in the event of impediment, the person instead appointed by board of directors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>3. Preparation and approval of the voting register</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>4. Approval of the agenda</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>5. Determination of whether the annual general meeting was duly convened</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)a. Resolution regarding adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)b. Resolution regarding allocation of the company's profit or loss according to the adopted balance sheet</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. Resolution regarding discharge from liability for board members and the managing director</b>
<b>7)c. 1 Jacob Gunterberg</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. 2 Heidi Hunter</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. 3 Maarten Kraan</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. 4 Sara Malcus</b> Yes <input type="checkbox"/> No <input type="checkbox"/>

<b>7)c. 5 Hans Schikan</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. 6 Michael Wolff Jensen</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. 7 Peter Ström</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. 8 Leif Darner</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7)c. 9 Carl Johan Dalsgaard</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8. Determination of the number of board members and auditors</b>
<b>8.1 Number of board members</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8.2 Number of auditors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9. Determination of the fees for the board of directors and the auditors</b>
<b>9.1 Fees to the board of directors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9.2 Fees to the auditors</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. Election of members of the board of directors</b>
<b>10. 1 Jacob Gunterberg (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. 2 Heidi Hunter (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. 3 Maarten Kraan (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. 4 Sara Malcus (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. 5 Hans Schikan (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. 6 Michael Wolff Jensen (re-election)</b> Yes <input type="checkbox"/> No <input type="checkbox"/>

<p><b>11. Election of the chairman of the board of directors</b>  <b>Michael Wolff Jensen (re-election)</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>12. Election of auditors and, where applicable, deputy auditors</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>13. Resolution on principles for appointing the nomination committee</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>14. Resolution on guidelines on remuneration to members of group management and board members</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>15. Presentation of the board of directors' remuneration report for approval</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>16. Resolution to authorize the board of directors to issue new shares</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>17. Resolution on the introduction of a long-term performance-based incentive program for certain members of the Board of Directors</b></p>
<p><b>17.a Proposal for resolution on adaption of a long-term performance-based incentive program for certain members of the Board of Directors</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>17.b Proposal regarding issue of warrants</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>17.c Equity swap agreement with a third part</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>18. Resolution on introduction of a long-term incentive program for the company's senior management and key persons</b></p>
<p><b>18.a Proposal regarding adoption of a long-term incentive program for certain senior management and key persons</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>18.b Proposal regarding issue of warrants</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>18.c Equity swap agreement with a third party</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p><b>19. Resolution to amend the articles of association</b></p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>

**The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting**

(Completed only if the shareholder has such a wish)

Item/items (use numbering):